Nordea Investment Management AB Has $144.25 Million Holdings in Pfizer Inc. $PFE

Nordea Investment Management AB increased its holdings in Pfizer Inc. (NYSE:PFE) by 51.9% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,930,075 shares of the biopharmaceutical company’s stock after acquiring an additional 2,026,502 shares during the period. Nordea Investment Management AB owned about 0.10% of Pfizer worth $144,249,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of PFE. GKV Capital Management Co. Inc. purchased a new stake in Pfizer in the 1st quarter worth about $27,000. North Capital Inc. purchased a new stake in Pfizer in the 1st quarter worth about $28,000. Bayforest Capital Ltd purchased a new stake in Pfizer in the 1st quarter worth about $28,000. Harbor Asset Planning Inc. purchased a new stake in Pfizer in the 2nd quarter worth about $29,000. Finally, Horizon Financial Services LLC purchased a new stake in Pfizer in the 1st quarter worth about $35,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

PFE has been the subject of a number of recent research reports. UBS Group reaffirmed a “neutral” rating and set a $28.00 price target on shares of Pfizer in a research note on Wednesday, October 1st. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a research note on Wednesday, October 8th. Wall Street Zen downgraded Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, September 28th. Bank of America increased their price objective on Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a report on Friday, October 3rd. Finally, Citigroup raised their price objective on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research note on Wednesday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $28.13.

Pfizer Stock Up 1.2%

Shares of PFE stock opened at $24.52 on Friday. The stock’s 50 day simple moving average is $24.89 and its 200 day simple moving average is $24.12. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $29.36. The company has a market capitalization of $139.38 billion, a price-to-earnings ratio of 13.04, a PEG ratio of 0.80 and a beta of 0.55.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. The firm had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company’s revenue was up 10.3% on a year-over-year basis. During the same quarter last year, the firm posted $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, research analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 7.0%. The ex-dividend date of this dividend is Friday, November 7th. Pfizer’s dividend payout ratio (DPR) is presently 91.49%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.